trending Market Intelligence /marketintelligence/en/news-insights/trending/JH9bYDa6BzqkcHWRmTdJNg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Canopy Growth closes deal for cannabis research firm, sells 13% stake in AusCann

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Canopy Growth closes deal for cannabis research firm, sells 13% stake in AusCann

Canopy Growth Corp. completed the acquisition of cannabinoid medical research company Beckley Canopy Therapeutics, including the joint venture Spectrum Biomedical UK.

Canopy Growth, in partnership with Beckley Research & Innovations, started a joint venture in January 2018 to form Beckley Canopy.

Ontario-based Canopy Growth will combine Beckley Canopy with its wholly owned research program that will support the commercial activities of Spectrum Therapeutics.

Canopy Growth did not disclose the financial terms of the transaction.

Additionally, Canopy Growth sold all owned shares of AusCann Group Holdings Ltd. for gross proceeds of C$6.3 million. The company sold 42,087,639 shares of the Australian Cannabis firm, representing a 13.2% stake.

Canaccord Australia facilitated the sale of shares that were sold through an off-market block at 15 Canadian cents apiece.

Canopy Growth's global senior director of clinical science, Marcel Bonn-Miller, will remain on AusCann's board.